Whitehawk Therapeutics
WHWK
15 hedge funds and large institutions have $47.5M invested in Whitehawk Therapeutics in 2018 Q2 according to their latest regulatory filings, with 15 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
1.97% more ownership
Funds ownership: 0% → 1.97% (+2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$20.9M |
| 2 |
AG
Artal Group
Luxembourg
|
+$6.28M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$4.45M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.54M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$3.08M |
Top Sellers
WHWK Hedge Fund Activity: Q2 2018 in Review
15 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q2 2018, worth a combined $47.5M.
Buyers outnumbered sellers: 15 funds opened new WHWK positions and 0 closed out — a net gain of 15 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $20.9M.
- 15 institutional investors held Whitehawk Therapeutics (WHWK) as of Q2 2018, up from 0 in Q1 2018.
- Funds reported $47.5M of Whitehawk Therapeutics stock for Q2 2018.
- 15 funds opened new Whitehawk Therapeutics positions in Q2 2018 and 0 closed out, a net change of +15 holders.
- The largest Whitehawk Therapeutics buyer in Q2 2018 was OrbiMed, an estimated $20.9M added.
Based on aggregated 13F filings for Q2 2018.